Genomic and proteomic screens by our lab and others have revealed tyrosine kinase 2 (TYK2) as an oncogene promoting progression and metastases of many types of carcinomas, sarcomas, and hematologic cancers. This evidence concerns the gene TYK2 and hematopoietic and lymphoid cell neoplasm.